KANEKO YASUNORI 4
4 · Arcus Biosciences, Inc. · Filed Mar 19, 2018
Insider Transaction Report
Form 4
KANEKO YASUNORI
Director
Transactions
- Conversion
Common Stock
2018-03-19+33,818→ 96,948 total(indirect: By Trust) - Conversion
Common Stock
2018-03-19+252,524→ 252,524 total(indirect: By LLC) - Conversion
Series A Convertible Preferred Stock
2018-03-19−505,050→ 0 total(indirect: By LLC)→ Common Stock (505,050 underlying) - Conversion
Series B Convertible Preferred Stock
2018-03-19−252,524→ 0 total(indirect: By LLC)→ Common Stock (252,524 underlying) - Conversion
Common Stock
2018-03-19+505,050→ 505,050 total(indirect: By LLC) - Conversion
Series B Convertible Preferred Stock
2018-03-19−31,253→ 0 total(indirect: By Trust)→ Common Stock (31,253 underlying) - Conversion
Series C Convertible Preferred Stock
2018-03-19−2,565→ 0 total(indirect: By Trust)→ Common Stock (2,565 underlying)
Footnotes (2)
- [F1]The total represents shares received upon conversion of shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock.
- [F2]The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.Q